Harmony Biosciences Holdings, Inc. operates as a commercial-stage pharmaceutical company dedicated to identifying, developing, and commercializing novel treatments for rare neurological disorders. The company's primary revenue driver is WAKIX (pitolisant), a small molecule histamine 3 (H3) receptor antagonist/inverse agonist marketed in the United States for adult patients with narcolepsy. Beyond its approved indications, Harmony is actively advancing a clinical pipeline that explores pitolisant for other rare central nervous system conditions, such as idiopathic hypersomnia and Prader-Willi syndrome. The company also seeks to expand its portfolio through strategic acquisitions and in-licensing agreements for late-stage assets. By focusing exclusively on rare neurological diseases, Harmony maintains a specialized commercial infrastructure targeting sleep specialists, neurologists, and psychiatrists.
